A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Running, not enrolling · Phase 3

Conditions studied: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

In brief

In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim of this study is to compare the number of participants on each treatment that show no signs of disease. Participants will take tablets of either ponatinib or imatinib at the same time each day combined with reduced-intensity chemotherapy for up to 20 months. Then, they will continue with single-agent therapy (ponatinib or imatinib) until they meet the discontinuation criteria from the study.

Key facts

Study ID

NCT03589326

Run by

Takeda

People needed

245

Starts

2018-10-04

Expected to finish

2027-07-31

Last updated by the study team

2025-11-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed Philadelphia chromosome-positive (Ph+) or BCR-ABL1-positive ALL, as defined by the 2017 national comprehensive cancer network (NCCN) guidelines.
• Eastern Cooperative Oncology Group (ECOG) performance status of <=2.

You may not qualify if…

• With a history or current diagnosis of chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML).
• Prior/current treatment with any systemic anticancer therapy (including but not limited to any tyrosine kinase inhibitor [TKI]) and/or radiotherapy for ALL, with the exception of an optional prephase therapy or chemotherapy induction (no more than 1 cycle), which should be discussed with the sponsor's medical monitor/designee.
• Currently taking drugs that are known to have a risk of causing prolonged corrected QT (QTc) or torsades de pointes (TdP) (unless these can be changed to acceptable alternatives or discontinued).
• Taking any medications or herbal supplements that are known to be strong inhibitors or strong inducers of cytochrome P450 (CYP)3A4 within at least 14 days before the first dose of study drug.
• Uncontrolled active serious infection that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
• Major surgery within 28 days before randomization (minor surgical procedures such as catheter placement or BM biopsy are not exclusionary criteria).
• Known human immunodeficiency virus (HIV) seropositivity, known active hepatitis B or C infection.
• History of acute pancreatitis within 1 year of study screening or history of chronic pancreatitis.
• Uncontrolled hypertriglyceridemia (triglycerides >450 milligram per deciliter [mg/dL]).
• Diagnosed and treated for another malignancy within 5 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
• History or presence of clinically relevant CNS pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.
• Clinical manifestations of CNS or extramedullary involvement with ALL other than lymphadenopathy or hepatosplenomegaly.
• Autoimmune disease with potential CNS involvement.
• Known significant neuropathy of Grade >=2 severity.
• Clinically significant, uncontrolled, or active cardiovascular, cerebrovascular, or peripheral vascular disease, or history of or active venous thrombotic/embolic event (VTE) disease.
• Have a significant bleeding disorder unrelated to ALL.

Where it is running

• City of Hope - Duarte — Duarte, California, United States
• University of California Los Angeles — Los Angeles, California, United States
• Augusta University Georgia Cancer Center — Augusta, Georgia, United States
• Indiana University — Indianapolis, Indiana, United States
• Indiana Blood & Marrow Transplantation — Indianapolis, Indiana, United States
• University of Kansas Medical Center Research Institute — Kansas City, Kansas, United States
• University of Maryland Medical Center — Baltimore, Maryland, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Monter Cancer Center — New Hyde Park, New York, United States
• Stony Brook University Medical Center — Stony Brook, New York, United States
• Oregon Health and Science University — Portland, Oregon, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Methodist Hospital — San Antonio, Texas, United States
• Sanatorio Allende — Córdoba, Argentina
• Hospital Privado Centro Medico de Cordoba — Córdoba, Argentina
• Royal North Shore Hospital — Saint Leonards, New South Wales, Australia
• Box Hill Hospital — Box Hill, Victoria, Australia
• Monash Medical Centre — Clayton, Victoria, Australia
• Hanusch Krankenhaus Wiener Gebietskrankenkasse — Vienna, State of Vienna, Austria
• Ordensklinikum Linz Elisabethinen — Linz, Upper Austria, Austria
• Universitaetsklinik Fuer Innere Medizin I — Vienna, Austria
• Hospital Sao Rafael-Monte Tabor — Salvador, Estado de Bahia, Brazil
• Hospital Erasto Gaertner — Curitiba, Paraná, Brazil
• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.